February has been internationally established as a month dedicated to cancer awareness, education, and prevention. Prevention and regular screening constitute our most powerful “weapon” for early diagnosis and effective treatment of the disease.
At Euromedica Group, with consistency and responsibility, we provide high-quality healthcare services, combining scientific accuracy, respect for the individual, and a firm commitment to the promotion of public health. As part of our Corporate Social Responsibility initiatives, and with the core message “Don’t postpone it. Prevent it.”, we offer throughout February, at a preferential price, four comprehensive cancer screening packages.
A. Prostate Screening
The PSA test (Prostate-Specific Antigen) is a first-line examination for the early detection of prostate cancer, as well as for the investigation of benign prostate conditions. It is recommended to be performed at least once a year for all men over the age of 45, either as a standalone test or in combination with other examinations.
B. Thyroid Screening
Thyroid cancer is the most common malignancy of the endocrine glands and occurs up to three times more frequently in women than in men. Despite its relatively high incidence, it is characterized in most cases by a favorable prognosis, particularly when diagnosed at an early stage and treated promptly with the appropriate therapeutic approach.
Preventive screening includes blood tests for:
• TSH
• FT3 & FT4
• Anti-TPO & Anti-TG antibodies
C. Tumor Marker Screening
Tumor markers are biological substances produced by the body that appear at elevated levels in cases of malignancy. Their measurement contributes to:
• early diagnosis
• prognosis assessment
• evaluation of treatment response
• monitoring of possible recurrences
The package includes the following markers:
• CEA (Carcinoembryonic Antigen): Associated with adenocarcinomas, mainly of the colon, lungs, and stomach.
• AFP (Alpha-Fetoprotein): Marker for liver cancer and cancers of the reproductive organs.
• CA 125: Useful biomarker for ovarian, endometrial, gastric, and colorectal cancers.
• CA 19-9: Elevated in gastrointestinal malignancies, such as pancreatic and gastric cancer.
• CA 15-3: Mainly associated with breast cancer and used for treatment monitoring.
• β-HCG (Human Chorionic Gonadotropin): Elevated in testicular cancer and choriocarcinoma.
D. Gynecological Screening
Cervical cancer is the second most common cancer among women aged 15–44 and is closely linked to chronic infection with the Human Papillomavirus (HPV). Despite its seriousness, it is largely preventable through regular screening, such as the Pap test, as well as through vaccination. Early diagnosis plays a decisive role in improving prognosis and reducing mortality.
Pap Test
The Pap test is a fundamental preventive examination, as it can detect precancerous and cancerous lesions of the cervix, as well as infections. It is recommended to be performed annually, starting from the onset of sexual activity and up to at least the age of 60.
Tumor Markers
• CA 125: For ovarian and endometrial cancer
• CA 15-3: For breast cancer and treatment monitoring
This initiative is valid from February 1st to February 28th, 2026. For more information, please contact the diagnostic center that serves you, either by phone or online via the “Book an Appointment” form.
Don’t postpone it. Prevent it.
